biote vs Natural Alternatives International
BTMD and NAII side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BTMD and NAII compare
biote is the larger company, worth 1.8 times as much as Natural Alternatives International ($35.6M against $19.9M).
Natural Alternatives International grew revenue faster over the last twelve months (9.7% versus −7.8% for biote).
biote keeps more of each dollar of sales as profit, with a net margin of 3.2% compared with −14.5% at Natural Alternatives International.
biote scores higher on the StockData Score (8 against 6 for Natural Alternatives International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BTMD | NAII |
|---|---|---|
| Size and price | ||
| Market cap | $35.6M | $19.9M |
| Share price | $0.990 | $0.901 |
| Change, 1 year | −60.7% | −71.6% |
| Change, 5 years | −89.8% | −93.1% |
| Beta (5Y) | 1.96 | 0.11 |
| Employees | 223 | 219 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 4 (better) | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 2 | 2 |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 9.9× | – |
| P/S | 0.2× | 0.1× (better) |
| P/B | – | 0.4× |
| EV/EBITDA | 8.3× | – |
| P/FCF | 1.8× | – |
| FCF yield | 55.9% (better) | −63.3% |
| Fair value | $3.20 | – |
| Margin of safety | 69.0% | – |
| Growth | ||
| Revenue growth (TTM) | −7.8% | 9.7% (better) |
| Revenue growth, 5Y average | – | −4.4% |
| Net income growth (TTM) | −81.3% | – |
| EPS growth (TTM) | −88.9% | – |
| Profitability | ||
| Gross margin | 68.6% (better) | 6.3% |
| Operating margin | 8.0% (better) | −13.2% |
| Net margin | 3.2% (better) | −14.5% |
| FCF margin | 10.8% (better) | −8.9% |
| Return on equity | – | −35.0% |
| Return on invested capital | 45.7% (better) | −25.2% |
| Financial health | ||
| Debt / equity | – | 0.20 |
| Net debt / EBITDA | 5.93 | – |
| Current ratio | 1.43 | 1.73 (better) |
| Altman Z-score | 1.87 (better) | 1.49 |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Payout ratio | 19.9% | – |
| Buyback yield | – | 0.45% |
| Shareholder yield | 0.00% | 0.45% (better) |
| Ownership | ||
| Held by institutions | 36.6% | 10.5% |
| Held by insiders | 23.3% | 5.0% |
| Insider net buying, 12 months | $202K (better) | $26.8K |
| Short interest, % of float | 3.1% | 0.03% |
Go deeper
- BTMD stock overview
- BTMD income statement
- BTMD valuation and score
- NAII stock overview
- NAII income statement
- NAII valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.